Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
August 13, 2018
AIT Therapeutics Announces $20 Million Common Stock Purchase Agreement with Institutional Investor, Lincoln Park Capital Fund
GARDEN CITY, N.Y., and REHOVOT, Israel, Aug. 13, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (AITB) (“AIT Therapeutics or the “Company”),  a clinical-stage medical device ...
August 10, 2018
Gemphire Announces Termination of Phase 2a Clinical Trial of Gemcabene in Pediatric NAFLD
LIVONIA, Mich., Aug. 10, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, ...
August 10, 2018
ADMA Biologics Reports Second Quarter 2018 Financial Results
RAMSEY, N.J. and BOCA RATON, Fla., Aug. 10, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”) today announced its financial results ...
August 10, 2018
Prometic announces the publication of PBI-4050's antifibrotic activity in liver diseases in Journal of Pharmacology and Experimental Therapeutics
LAVAL, QC , Aug. 10, 2018 /CNW Telbec/ - Prometic Life Sciences Inc. (PLI.TO) (PFSCF) ("Prometic") today announced the publication of a paper further elucidating the ...
August 10, 2018
Eiger BioPharmaceuticals Reports Second Quarter 2018 Financial Results
PALO ALTO, Calif., Aug. 10, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today ...
August 9, 2018
Sierra Oncology Reports Second Quarter Results
VANCOUVER, Aug. 9, 2018 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) ...
August 9, 2018
InflaRx N.V. Reports Second Quarter 2018 Financial & Operating Results
JENA, Germany, Aug. 09, 2018 (GLOBE NEWSWIRE) -- InflaRx N.V. (IFRX), a biopharmaceutical company developing innovative therapeutics to treat life-threatening inflammatory diseases by targeting the ...
August 9, 2018
Mustang Bio to Present at 10th Annual Bioprocessing Summit
NEW YORK, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (MBIO), a Fortress Biotech (FBIO) Company focused on the development of novel immunotherapies ...
August 9, 2018
Relmada Therapeutics Allowed Patent Application in China Covering NMDA Receptor Antagonist d-Methadone for Treatment of Psychiatric Symptoms
NEW YORK, Aug. 9, 2018 /PRNewswire/ -- Relmada Therapeutics, Inc. (RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) ...
August 9, 2018
Aeglea BioTherapeutics Provides Corporate Update and Reports Second Quarter 2018 Financial Results
AUSTIN, Texas, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for ...
August 9, 2018
Krystal Biotech’s KB105 Granted Orphan Drug Designation by the FDA to Treat Patients With TGM-1 Deficient Autosomal Recessive Congenital Ichthyosis
PITTSBURGH, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering ...
August 9, 2018
HTG Molecular Announces Amendment to Second Statement of Work with QIAGEN Manchester Limited
TUCSON, Ariz., Aug. 09, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications, today ...
August 9, 2018
Aeglea BioTherapeutics Provides Corporate Update and Reports Second Quarter 2018 Financial Results
AUSTIN, Texas, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for ...
August 9, 2018
PolarityTE, Inc. Announces the Addition of Ramses Erdtmann, Managing Partner at Point Sur Investors and Former Executive at Pharmacyclics, and David Seaburg, Managing Director at Cowen and CNBC Contributor, to the Board of Directors
SALT LAKE CITY, Aug. 09, 2018 (GLOBE NEWSWIRE) -- PolarityTE, Inc. (COOL), a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of ...
August 9, 2018
Athenex Pharmaceutical Division Receives FDA Clearance to Import Potassium Chloride Injection Concentrate to Address U.S. Drug Shortage
BUFFALO, N.Y., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel ...
August 9, 2018
Vaccinex Announces Pricing of Initial Public Offering
ROCHESTER, N.Y., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Vaccinex), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to ...
August 9, 2018
RedHill Biopharma Announces Pricing of $25 Million Underwritten Offering
TEL-AVIV, Israel and RALEIGH, N.C., Aug. 09, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty ...
August 6, 2018
miRagen Therapeutics and The Leukemia & Lymphoma Society® Enter Into an Agreement to Facilitate the Development of Cobomarsen in Cutaneous T-Cell Lymphoma
BOULDER, Colo. and RYE BROOK, N.Y., Aug. 06, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and ...
August 6, 2018
Neovasc to Present at the 38th Annual Canaccord Genuity Growth Conference
VANCOUVER, Aug. 6, 2018 /PRNewswire/ - Neovasc, Inc. ("Neovasc" or the "Company") (NVCN) (NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement ...
August 6, 2018
Neovasc Announces Publication of Safety and Efficacy Results from REDUCE Study in International Journal of Cardiology
VANCOUVER, Aug. 6, 2018 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN) (NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, ...
Page 33 of 127